Clinical Trials Directory

Trials / Terminated

TerminatedNCT01071564

RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery

A Phase I Study of the Hedgehog Smoothened Antagonist GDC-0449 (NSC # 747691) Plus Pan-Notch Inhibitor RO4929097 (NSC # 749225) Administered in Patients With Advanced Breast Cancer

Status
Terminated
Phase
Phase 1
Study type
Interventional
Enrollment
13 (actual)
Sponsor
National Cancer Institute (NCI) · NIH
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This phase I trial studies the side effects and best dose of RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097) when given together with vismodegib in treating patients with breast cancer that is metastatic or cannot be removed by surgery. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vismodegib, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving RO4929097 and vismodegib together may slow the growth of tumor cells and may be a more active treatment for advanced breast cancer.

Detailed description

PRIMARY OBJECTIVES: I. To determine the safety and tolerability of continuous daily administration of 150 mg/day of GDC0449 (vismodegib) in combination with escalating doses of RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097) administered on a repeated schedule of days 1-3, 8-10 every 21 days (for a total of 6 days of RO4929097 administration per 21 day cycle) in patients with advanced breast cancer. II. To determine the dose limiting toxicity (DLT) and identify the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) for this administration schedule. SECONDARY OBJECTIVES: I. To determine the pharmacokinetics (PK) and pharmacogenetics (PG) of GDC0449 and RO4929097, each alone and in combination. II. To attempt to evaluate select pharmacodynamic (PD) stem cell differentiation biomarkers in the hedgehog and notch signaling pathways (e.g. GLI family zinc finger \[Gli\]1/2/3, patched \[Ptch\] 1/2, hairy and enhancer of split 1, \[Drosophila\] \[Hes1\], huntingtin interacting protein 1 \[Hip1\], hairy/enhancer-of-split related with YRPW motif 1 \[Hey1\], Notch4, Jagged1, numb homolog \[Drosophila\] \[numb\], BMI1 polycomb ring finger oncogene \[Bmi-1\], cluster of differentiation \[CD\]44/CD24, aldehyde dehydrogenase \[ALDH\] proto-oncogene tyrosine-protein kinase \[Src\] family kinases) and the percentage of breast cancer stem cell (BCSC) in serial breast tumor biopsies before and after GDC0449 or RO4929097 alone and after 1 cycle of treatment with the combination of GDC0449 and RO4929097. III. To determine tumor response in patients with measurable disease as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). IV. To perform molecular profiling of the tumor cell and BCSC populations before and after GDC0449 or RO4929097 alone and after 1 cycle of treatment with the combination of GDC0449 and RO4929097 at the MTD. OUTLINE: This is a dose-escalation study of gamma-secretase/Notch signalling pathway inhibitor RO4929097. Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 orally (PO) on day 1 or days -2, -1, and 1 of course 1 and days 1-3 and 8-10 of course 2 and all subsequent courses. Patients also receive vismodegib PO once daily (QD) beginning day 8 of course 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 30 days.

Conditions

Interventions

TypeNameDescription
DRUGGamma-Secretase Inhibitor RO4929097Given PO
OTHERLaboratory Biomarker AnalysisCorrelative studies
OTHERPharmacogenomic StudyCorrelative studies
OTHERPharmacological StudyCorrelative studies
DRUGVismodegibGiven PO

Timeline

Start date
2009-11-01
Primary completion
2014-06-01
Completion
2014-06-01
First posted
2010-02-19
Last updated
2015-04-15

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01071564. Inclusion in this directory is not an endorsement.